share_log

Skylight Health Announces Earnings Call and Corporate Update

Skylight Health Announces Earnings Call and Corporate Update

Skylight Health宣佈財報電話會議和公司最新情況
GlobeNewswire ·  2022/05/12 05:29

TORONTO, May 11, 2022 (GLOBE NEWSWIRE) -- Skylight Health Group Inc. (NASDAQ:SLHG;TSXV:SLHG ("Skylight Health" or the "Company"), a multi-state primary care management group in the United States, today announced that its financial results for the first quarter of 2022 will be released after the close of market on May 16th, 2022. The Company will host a conference call at 8:00am EDT on the morning of May 17th, 2022 to discuss the financial results and outlook for the Company.

環球通訊社多倫多,2022年5月11日-美國多州初級保健管理集團天光健康集團(納斯達克:SLHG;多倫多證券交易所股票代碼:SLHG;多倫多證券交易所股票代碼:SLHG)今天宣佈,其2022年第一季度的財務業績將於2022年5月16日市場收盤後公佈。該公司將於美國東部時間2022年5月17日上午8:00舉行電話會議,討論公司的財務業績和前景。

If you would like to participate in the call, details can be found below. Please dial in approximately 10 minutes prior to the start of the call.

如果您想參加電話會議,可以在下面找到詳細信息。請在通話開始前大約10分鐘撥打電話。

Conference Call Details

電話會議詳細信息

Date: May 17, 2022
Time: 8:00am Eastern
US/Canada Toll Free Dial In: 1-800-319-4610
Toronto Local Dial In: 416-915-3239
International Dial In: +1-604-638-5340
Call Name: Skylight Health Group First Quarter 2022 Financial Results
日期: 2022年5月17日
時間: 東部時間上午8:00
美國/加拿大免費撥入: 1-800-319-4610
多倫多本地撥入: 416-915-3239
國際撥入: +1-604-638-5340
呼叫名稱: 天光健康集團2022年第一季度財務業績


The Company is also announcing that it has received a notice ("Notice") from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") as a result of its failure to timely file its Annual Report on Form 20-F for the year ended December 31, 2021 (the "Form 20-F") as established in Nasdaq Listing Rule 5250(c)(1) (the "Rule"). The Form 20-F is the required annual report that the Company should file with the US Securities and Exchange Commission ("SEC") that incorporates its annual financial statements which were completed and previously filed with the SEC under Form 6-K on March 30, 2022. Due to the additional PCAOB audit requirements for the fiscal years ended December 31, 2020 and 2019, which were not required upon the Company's initial listing in the US and on Nasdaq, the Company has not been able to file the Form 20-F on time.


本公司亦宣佈,已收到納斯達克證券市場(“納斯達克”)上市資格審核部發出通知(“通知”),因其未能按照“納斯達克上市規則”第5250(C)(1)條(“該規則”)的規定,及時提交其截至2021年12月31日止年度的20-F表格年報(“20-F表格”)。Form 20-F是公司應向美國證券交易委員會(“美國證券交易委員會”)提交的必需的年度報告,其中包括已於2022年3月30日以Form 6-K向美國證券交易委員會完成並提交的年度財務報表。由於PCAOB對截至2020年12月31日和2019年12月31日的財政年度的額外審計要求,而這些要求在公司在美國和納斯達克首次上市時並未被要求,公司未能按時提交20-F表格。

While the Company works to rectify this non-compliance with its US filing requirements, trading of the Company's shares continues without issue on Nasdaq and TSX-V.

雖然公司正在努力糾正這種不遵守其美國備案要求的行為,但公司股票在納斯達克和多倫多證交所-V的交易仍未發行。

The Notice also disclosed that under Nasdaq rules, the Company has 60 calendar days from receipt of the Notice, or until July 5, 2022, to submit a plan to regain compliance with the Rule. Upon Nasdaq approval of the Company's plan, it may grant an exception of up to 180 calendar days from the due date of the Form 20-F, or until October 31, 2022, to regain compliance. However, there can be no assurance that Nasdaq will accept the Company's plan to regain compliance or that the Company will be able to regain compliance within any extension period granted by Nasdaq.

通知還披露,根據納斯達克規則,公司有60個日曆日的時間在收到通知後,或在2022年7月5日之前提交計劃,以重新遵守規則。在納斯達克批准公司的計劃後,公司可給予自20-F表格到期日起最長180個歷日的例外,或至2022年10月31日為止,以重新獲得合規。然而,不能保證納斯達克會接受公司恢復合規的計劃,也不能保證公司能夠在納斯達克批准的任何延長期內恢復合規。

The Company is also announcing the issuance of 318,259 shares which is the final issuance related to its previously announced acquisition of River City Medical Associates announced on February 4, 2021. All issued shares will be subject to a four-month hold from the date of issuance and is subject to TSX-V approval. This is the last issuance of shares being made in relation to this acquisition.

該公司還宣佈發行318,259股,這是與2021年2月4日宣佈的對River City Medical Associates的收購相關的最後一次發行。所有已發行股票將自發行之日起持有四個月,並有待多倫多證交所-V的批准。這是與此次收購相關的最後一次股票發行。

About Skylight Health Group 

關於天光健康集團

Skylight Health Group (NASDAQ:SLHG;TSXV:SLHG) is a healthcare services and technology company, working to positively impact patient health outcomes. The Company operates a US multi-state primary care health network comprised of physical practices providing a range of services from primary care, sub-specialty, allied health, and laboratory/diagnostic testing. The Company is focused on helping small and independent practices shift from a traditional fee-for-service (FFS) model to value-based care (VBC) through tools including proprietary technology, data analytics and infrastructure. In an FFS model, payors (commercial and government insurers) reimburse on an encounter-based approach. This puts a focus on volume of patients per day. In a VBC model, the providers offer care that is aimed at keeping patients healthy and minimize unnecessary health expenditures that are not proven to maintain the patient's well-being. This places an emphasis on quality over volume. VBC will lead to improved patient outcomes, reduced cost of delivery and drive stronger financial performance from existing practices.

天光健康集團(納斯達克:SLHG;多倫多證券交易所股票代碼:SLHG)是一家醫療服務和技術公司,致力於積極影響患者的健康結果。該公司經營着美國多個州的初級保健保健網絡,由物理實踐組成,提供從初級保健、專科、聯合保健和實驗室/診斷測試在內的一系列服務。該公司專注於通過包括專有技術、數據分析和基礎設施在內的工具,幫助小型獨立實踐從傳統的按服務收費(FFS)模式轉變為基於價值的護理(VBC)模式。在FFS模式中,付款人(商業和政府保險公司)根據相遇的方法進行報銷。這將重點放在每天的病人數量上。在VBC模式中,提供者提供的護理旨在保持患者的健康,並將未經證明能夠維持患者福祉的不必要的醫療支出降至最低。這就把重點放在質量而不是數量上。VBC將改善患者的預後,降低交付成本,並從現有實踐中推動更強勁的財務業績。

Forward Looking Statements

前瞻性陳述

This press release may include predictions, estimates or other information that might be considered forward-looking within the meaning of applicable securities laws. While these forward-looking statements represent our current judgments, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this release. Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events. When used herein, words such as "look forward," "believe," "continue," "building," or variations of such words and similar expressions are intended to identify forward-looking statements. Factors that could cause actual results to differ materially from those contemplated in any forward-looking statements made by us herein are often discussed in filings we make with the Canadian and United States securities regulators, including the Securities and Exchange Commission, available at: www.sec.gov, and Canadian Securities Administrators, available at , and on our website, at skylighthealthgroup.com.

本新聞稿可能包括可能被視為適用證券法意義上的前瞻性的預測、估計或其他信息。雖然這些前瞻性陳述代表了我們目前的判斷,但它們會受到風險和不確定性的影響,這些風險和不確定性可能會導致實際結果大不相同。告誡您不要過度依賴這些前瞻性陳述,這些陳述僅反映我們截至本新聞稿發佈之日的觀點。請記住,我們沒有義務根據新信息或未來事件修改或公開發布對這些前瞻性陳述的任何修訂結果。在此使用時,諸如“展望”、“相信”、“繼續”、“建設”等詞語或此類詞語的變體和類似表達旨在識別前瞻性陳述。可能導致實際結果與我們在此作出的任何前瞻性陳述中預期的結果大不相同的因素經常在我們向加拿大和美國證券監管機構(包括美國證券交易委員會)提交的文件中討論,這些文件可在www.sec.gov和加拿大證券管理人的網站和skylighthealthgroup.com上獲得。

For more information, please visit our website or contact:

欲瞭解更多信息,請訪問我們的網站或聯繫:

Investor Relations:
Jackie Kelly
investors@skylighthealthgroup.com416-301-2949  

投資者關係:
傑基·凱利
電子郵件:Investors@skylighthealthgroup.com416-301-2949

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

多倫多證券交易所創業板交易所及其監管服務提供商(該術語在多倫多證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論